Genmab A/S reaffirmed financial guidance for 2024. The company's revenue guidance is unchanged and expected to be in the previously disclosed guidance range of DKK 18.7 billion ? DKK 20.5 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,806 DKK | +0.50% |
|
-1.45% | -16.19% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.19% | 16.51B | |
+15.19% | 122B | |
+19.91% | 113B | |
+8.24% | 22.84B | |
-19.80% | 20.72B | |
-13.45% | 16.39B | |
-44.35% | 15.83B | |
+2.13% | 13.49B | |
+66.67% | 11.67B | |
+119.39% | 10.43B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab A/S Reaffirms Financial Guidance for 2024